It's smart to disclose that your drug is addictive

Failing to mention a medicine’s addictive proclivities is a major no-no these days, given the raging epidemic of prescription drug abuse. But that’s exactly what Galt Pharmaceuticals seems to have done with its insomnia drug Doral, according to an FDA warning letter sent earlier this month.

Regulators say Galt sent an email to doctors extolling the purported benefits of Doral over its competitors, while leaving out the fact that it’s classified a Schedule IV controlled substance. 

Read more.